The State Of AI In Clinical Trials: Today And Tomorrow

To better understand how artificial intelligence (AI) is currently being used in clinical trials, Medidata commissioned ISR Market Research to conduct a comprehensive survey targeting both current and prospective AI users. The study explored a wide range of topics, including organizational adoption of AI, current applications, areas of greatest value, barriers to implementation, and realized benefits compared to expectations.

Respondents ranged from managers to C-suite executives and represented diverse functional areas such as clinical operations, data management, data science, therapeutic leadership, digital innovation, and patient recruitment and engagement.

The findings were highly encouraging. Sixty percent of all participants — both AI users and non-users — reported being either extremely or moderately knowledgeable about AI in clinical trials. Moreover, the adoption of AI is clearly accelerating: 4% of AI-using organizations reported leveraging AI in the majority of their trials, 22% have implemented it in some trials, and 30% are currently in the process of adoption. Another 37% indicated they are actively exploring AI applications, while only 7% have no plans to adopt AI within the next 12 months, a surprisingly high figure given the significant advantages already observed among adopters.

Overall, the study underscores a remarkable opportunity for organizations that have yet to define their AI strategy. However, the window for competitive differentiation is closing rapidly. Companies that delay AI adoption risk falling behind in an increasingly data-driven and innovation-focused clinical research landscape.

Gain further insight into how AI is being utilized in clinical trials by accessing the download below.